Undetectable measured serum bicarbonate associated with hypertriglyceridemia-induced pancreatitis

Veltri, Nicole; Chan, Michael K.; Awad, Sara

doi:10.1503/cmaj.200237

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the recurrence rate of HTG-AP was significantly higher than that of AP of other etiologies [ 10 , 20 ]. Elevated TG levels in HTG-AP lead to more free fatty acids released during pancreatic lipase hydrolysis than in AP induced by other causes [ 21 ], contributing to the development of systemic inflammatory response syndrome (SIRS) and progression to hyperlipidemic severe acute pancreatitis (HLSAP) [ 10 , 22 ], with more severe pancreatic necrosis later in the course of the disease.…”

Section: Introductionmentioning

confidence: 99%

Evaluating the efficacy and timing of blood purification modalities in early-stage hyperlipidemic acute pancreatitis treatment

Wang,

Xia,

Cao

et al. 2023

Lipids Health Dis

View full text Add to dashboard Cite

Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is characterized by a violent cytokine storm-driven inflammation and is associated with a predisposition to severe disease. The treatment strategy for HTG-AP consists mainly of conventional symptomatic and lipid-lowering treatments. For early-stage HTG-AP, blood purification (BP) can rapidly and effectively reduce serum triglyceride and inflammatory cytokine levels, block the development of systemic inflammatory response syndrome, and improve patient outcomes. Currently, the primary modalities for BP in patients with HTG-AP include plasma exchange, hemoperfusion, and hemofiltration. When using BP to treat patients with HTG-AP, a comprehensive analysis incorporating the elevated lipid levels and severity of the patient’s condition contributes to the selection of different treatment modes. Moreover, the timing of the treatment is also imperative. Early intervention is associated with a better prognosis for patients with HTG-AP requiring lipid-lowering treatment.

show abstract

Section: Introductionmentioning

confidence: 99%